publications and clinical research supporting aiq technologies

Description of technology

- Vanderhoek M, Juckett MB, Perlman S, et al.  Early assessment of treatment response in patients with AML using [18F]FLT PET imaging. Leuk Res. 2011;35(3):310–316.

- Yip S, Perk T, Jeraj R. Development and evaluation of an articulated registration algorithm for human skeleton registration. Phys Med Biol. 2014;59(6):1485-1499.

- Yip S, Jeraj R. Use of articulated registration for response assessment of individual metastatic bone lesions. Phys Med Biol. 2014;59(6):1501-1514.

- Simoncic U, Perlman S, Liu G, et al.  Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer. 2015;13(1):e7-17.

- Muzahir S, Jeraj R, Liu G, et al.  Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with 18F-NaF PET/CT in castrate resistant prostate cancer patients. Am J Nucl Med Mol Imaging. 2015;5(2):162-168.

- Perk T, Weisse N, Yip SF, Jeraj R. A method for quantitative total marrow imaging (QTMI) with PET/CT. Biomed Phys Eng Express. 2016;2(5).

- Harmon S, Bergvall E, Mena E, et al.  A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer. J Nucl Med. 2018;59(11):1665-1671.

- Perk T, Chen S, Harmon S, et al.  A statistically optimized regional thresholding method (SORT) for bone lesion detection in 18F-NaF PET/CT imaging. Phys Med Biol. 2018;63(22).

- Perk T, Bradshaw T, Chen S, et al.  Automated classification of benign and malignant lesions in 18F-NaF PET/CT images using machine learning. Phys Med Biol. 2018;63(22).

Technology robustness and repeatability

- Lin C, Bradshaw T, Perk T, et al.  Repeatability of quantitative 18F-NaF PET: a multicenter study. J Nucl Med.2016;57(12):1872-1879.

Correlation between analysis and clinical outcomes

- Harmon SA, Perk T, Lin C, et al.  Quantitative assessment of early [18F]sodium fluoride positron emission tomography/computed tomography response to treatment in men with metastatic prostate cancer to bone. J Clin Oncol.2017;35(24):2829-2837.

- Scarpelli M, Zahm C, Perlman S, et al.  FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. J Immunother Cancer. 2018;7(23).

Biological validation

- Roth A, Tomlins SA, Tuite M, et al.  Targeting differential response using molecular guided biopsies in bone-metastatic prostate cancer. J Clin Oncol 2019;37(suppl; abstr e16516).

Valuable intelligence at the time of patient management decision making

- Kyriakopoulos CE, Heath EI, Ferrari A, et al.  Interlesional Response Assessment With 18F-SodiumFluoride (18F-NaF) PET/CT in Men With Chemotherapy-Naive Bone Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide. Poster presented at 2019 American Society for Clinical Oncology Annual Meeting; June, 2019; Chicago, IL.

- Liu G, Kyriakopoulos CE, Lang JM, et al.  Spatial-Temporal Change in Quantitative Total Bone Imaging and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. Poster presented at ESMO Congress 2019; Sep 2019; Barcelona, Spain.

- Jeraj R, Mattison R, Kostakoglu L, et al.  EAI141: Early Assessment of Treatment Response in AML using [18F]FLT PET/CT Imaging. Oral presentation at: ECOG-ACRIN Spring 2019 Group Meeting; May, 2019; Boston, MA.

- McNeel DG, Eickhoff JC, Johnson LE, et al.  Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. J Clin Oncol. 2019;37(36):3507-3517.

- Perk TG, Yip S, Jeraj R, Perlman SB. Spatiotemporal evolution of lesion response heterogeneity to 177Lu-DOTATATE therapy in advanced gastroenteropancreatic neuroendocrine tumors. Poster presented at SNMMI 2020 Annual Meeting; Jul 2020; virtual.

- Ongoing clinical trial: Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: the CHAARTED2 Trial:  A trial of the ECOG-ACRIN Cancer Research Group (EA8153).

This document contains claims that have not been reviewed by the FDA.  For information about applications in commercial distribution for patient management, see www.aiq-solutions.com/customers/hospitals